Relapsed/Refractory Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma (NHL). It begins in the mantle zone (the outer area of small lymphocytes surrounding a lymphatic nodule). Sometimes MCL cells enter the lymphatic channels and blood to spread to other lymph nodes or tissues (eg, bone marrow, liver, or gastrointestinal tract).

MCL accounts for approximately 5% of all NHL cases in the United States and Europe. Incidence is estimated at 4 to 8 people per million, per year. While rare, MCL is an aggressive form of NHL that is often diagnosed at an advanced stage. MCL is incurable in most people, however, prompt diagnosis and treatment can reduce disease progression and may result in complete remission for years.

In addition, there have been major advancements in treatment options in recent years. New drug approvals include Bruton Tyrosine Kinase (BTK) inhibitors, ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib), proteosome inhibitors (bortezomib), and cellular therapies (ie, CAR T-cell therapies).

If you have any questions about this project, please contact the ACCC Provider Education department.